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We recently isolated 20(S)-25-methoxyl-dammarane-3b,1 2 b, 20-triol (25-OCH3-PPD), a natural product from Panax notoginseng,
and demonstrated its cytotoxicity against a variety of cancer cells. Here we report the effects of this compound in vitro and in vivo on
human prostate cancer cells, LNCaP (androgen-dependent) and PC3 (androgen-independent), in comparison with three structurally
related ginsenosides, ginsenoside Rh2, ginsenoside Rg3, and 20(S)-protopanaxadiol. Of the four test compounds, 25-OCH3-PPD was
most potent. It decreased survival, inhibited proliferation, induced apoptosis, and led to G1 cell cycle arrest in both cell lines. It also
decreased the levels of proteins associated with cell proliferation (MDM2, E2F1, cyclin D1, and cdks 2 and 4) and increased or
activated pro-apoptotic proteins (cleaved PARP, cleaved caspase-3, -8, and -9). In LNCaP cells, 25-OCH3-PPD inhibited the
expression of the androgen receptor and prostate-specific antigen. Moreover, 25-OCH3-PPD inhibited the growth of prostate
cancer xenograft tumours. Combining 25-OCH3-PPD with conventional chemotherapeutic agents or with radiation led to potent
antitumour effects; tumour regression was almost complete following administration of 25-OCH3-PPD and either taxotere or
gemcitabine. 25-OCH3-PPD also demonstrated low toxicity to noncancer cells and no observable toxicity in animals. In conclusion,
our preclinical data indicate that 25-OCH3-PPD is a potential therapeutic agent against both androgen-dependent and androgen-
independent prostate cancer.
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Prostate cancer poses a major public health problem worldwide. In
the United States, it is the most frequently diagnosed cancer, and
the third leading cause of cancer death in men (American Cancer
Society, Inc., 2007). Since androgen- and androgen receptor
(AR)-mediated signalling are often essential for the initiation
and progression of prostate cancer (Feldman and Feldman, 2001;
Heinlein and Chang, 2004), targeting the receptor and/or its
signalling pathways represents a rational strategy for treating this
disease (Kelloff et al, 1999; Bosland et al, 2002). Although
antiandrogens provide effective treatment for some prostate
cancers, many patients develop androgen-independent tumours
that are generally more aggressive, more resistant to the presently
used chemotherapeutic agents, and more likely to metastasise
(Tammela, 2004; Petrylak, 2005; Quinn et al, 2005). Thus, there is
an urgent need for novel therapeutic agents to improve the
outcome of antiprostate cancer therapy. Especially desirable are
compounds that are structurally different from those currently
used and novel agents that inhibit cell-cycle progression, induce
apoptosis, and target multiple aspects of AR-dependent and
AR-independent signalling.
Natural products provide a rich source for developing novel
anticancer agents. We have recently been interested in evaluating
the anticancer activity of ginseng and related herb medicines.
Ginseng is used in many cultures, especially in China and other
Asian countries, for the treatment and prevention of various
diseases, including cancer (Helms, 2004). People who consume
ginseng preparations are at lower risk for cancers of the oral cavity,
stomach, lung, liver, pancreas, ovaries, and colon (Yun, 2003).
Panax ginseng (Korean ginseng), Panax quinquefolius (American
ginseng), and other related plants, including Panax notoginseng/
pseudoginseng (P. notoginseng, Buck FH Chen), are frequently
used for medicinal purposes. In the United States, ginseng is one
of the most widely used medicinal herbs (O’Hara et al, 1998).
Although only part of the complex mixture of compounds present
in these plants, the ginsenosides (saponin triterpene glycosides),
are apparently responsible for most of the pharmacological effects
of ginseng and notoginseng. Some ginsenosides assert anticancer
properties by decreasing DNA synthesis and angiogenesis,
reducing host susceptibility to mutation, transformation, and
DNA damage, and increasing immunosurveillance and apoptosis
(Li, 1995; Attele et al, 1999; Kitts and Hu, 2000; Shibata, 2001; Xie
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set al, 2005). Ginsenosides also enhance the effects of traditional
chemotherapeutic agents and protect normal host tissue from
damage (Sato et al, 1994; Nakata et al, 1998; Helms, 2004; Wang
et al, 2006; Xie et al, 2006).
We recently isolated a novel ginsenoside, 20(S)-25-methoxyl-
dammarane-3b,1 2 b, 20-triol (25-OCH3-PPD), from P. notoginseng,
and determined that it might have utility as an anticancer
agent, with a better in vitro anticancer profile compared with
other analogues (Zhao et al, 2007). In this study, we further
evaluated this compound for its effects against prostate cancer,
emphasising in vivo activity, molecular mechanisms, and combi-
nation therapy. In addition, to demonstrate its potency, three
compounds with related structures (ginsenoside Rh2 (Rh2),
ginsenoside Rg3 (Rg3), and 20(S)-protopanaxadiol (PPD)) were
included.
MATERIALS AND METHODS
Test compounds
The isolation and structural characterisation of 25-OCH3-PPD
(from P. notoginseng) and related compounds Rg3, Rh2, and PPD
(from P. ginseng) were previously accomplished and described
(Wang et al, 2007; Zhao et al, 2007). For isolation of 25-OCH3-
PPD, dried leaves of P. notoginseng (Buck FH Chen) were extracted
with 70% ethanol, and the extract was passed through a
macroreticular resin column. The saponin fraction was dried,
hydrolysed with 18% HCl, and extracted with ethyl acetate. The
saponins were then separated by silica gel and preparative reverse-
phase chromatography to yield 25-OCH3-PPD (Zhao et al, 2007),
which was not found in substantial quantities in P. ginseng.
Reagents
All chemicals and solvents were of the highest analytical grade
available. Cell culture supplies were obtained from the Compre-
hensive Cancer Center Media Preparation Shared Facility
(University of Alabama at Birmingham). Anti-human MDM2
(SMP14), p21 (C-19), Bcl-2 (100), Bax (N-20), E2F1 (KH95),
p27 (C-19), CDK2 (M2), CDK4 (H-22), CDK6 (C-21), cyclin D1
(DCS-6), and PARP (H-250) antibodies were from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). The anti-human p53
(Ab-6) antibody was from EMD Chemicals Inc. (Gibbstown, NJ,
USA). An anti-human antibody for prostate-specific antigen (PSA)
was purchased from Dako (Glostrup, Denmark), and an anti-
human antibody for the AR was purchased from BD Pharmingen
(San Diego, CA, USA). The anti-human caspase-3 (9662), caspase-8
(9746), and caspase-9 (9502) antibodies were from Cell Signaling
Technology Inc. (Danvers, MA, USA).
Cell cultures
Human LNCaP (p53 wild-type, androgen-dependent) and PC3
(p53 null, androgen-independent) cells, obtained from the
American Type Culture Collection (Rockville, MD, USA), were
cultured as described previously (Wang et al, 2007). The human
primary fibroblast cell lines IMR90-EEA and IMR90-E1A (trans-
formed using the adenoviral oncogene E1A) were gifts from Dr S
Lee (Harvard University, Boston, MA, USA). IMR90-EEA and
IMR90-E1A cells were cultured in DMEM medium. All culture
media contained 10% fetal bovine serum and 1% penicillin–
streptomycin.
Evaluations of cell survival, proliferation, apoptosis, and
cell cycle distribution
For these experiments, the ginsenosides were dissolved in
dimethylsulphoxide and added to the culture media so that the
concentration of the solvent was 0.1%. As described previously
(Wang et al, 2007), effects of the test compounds on human cancer
cell growth and survival were determined by the use of 3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
Their effects on cell proliferation were evaluated by bromodeoxy-
uridine incorporation (Oncogene, La Jolla, CA, USA), following a
previously reported protocol (Wang et al, 1999). Cells in the
early and late stages of apoptosis were detected by use of an
Annexin V-FITC apoptosis detection kit from BioVision
(Mountain View, CA, USA), as previously described (Wang et al,
1999). For determination of the effects on the cell cycle, 2 to 3 10
5
cells were exposed to the test compounds (0, 1, 5, 10, 25, or 50mM)
and incubated for 24h before analysis. Cells were trypsinised,
washed with phosphate-buffered saline (PBS), and fixed in 1.5ml
of 95% ethanol at 41C overnight, followed by incubation
with RNAse and staining with propidium iodide (Sigma Chemical
Co., St Louis, MO, USA). The DNA content was determined by
flow cytometry. The levels of selected proteins were assessed by
western blots using methods described previously (Wang et al,
1999). In these studies, cells were exposed to various concentra-
tions of the four compounds for 24h. The proteins of interest
were detected by enhanced chemiluminescence reagents from
Perkin Elmer LAS Inc. (Boston, MA, USA). Resveratrol, a control
natural product in AR and PSA experiments, was obtained from
Sigma.
Determination of PSA protein
An assay kit (no. CM-401) from United Biotech Inc. (Mountain
View, CA, USA) was used to measure secreted and cellular PSA
following a method previously reported (Cho et al, 2004). Before
exposure began, LNCaP cells, which produce PSA in response to
androgen stimulation (Langeler et al, 1993), were washed three
times with PBS to reduce background PSA. A fresh medium
containing a test compound was added, and after 72h, samples of
media were collected and centrifuged to remove detached cells. In
addition, cell lysates were prepared in PBS by freezing and thawing
collected cells for three cycles followed by sonication for 15s. The
supernatant obtained after centrifugation (16000g, 20min, 41C)
was collected and stored at  201C. For normalisation of results,
protein contents of the lysates were determined by the Lowry
method.
Reverse transcriptase–polymerase chain reaction for
mRNA of PSA, AR, neuron-specific enolase, and
glyceraldehyde-3-phosphate dehydrogenase
A Qiagen RNeasy kit (cat no. 74104, Valencia, CA, USA) was used
to extract RNA from LNCaP cells exposed to test compounds for
24h. Reverse transcription was performed with 3–4mg total RNA
and oligo(dT) primers using SuperScriptt II RT (cat no. 18064-
014, GIBCO-BRL, Foster City, CA, USA). PCR was accomplished by
use of the Qiagen HotStarTaq Master Mix Kit (cat no. 203445)
under optimised conditions for detecting differences in transcript
abundance. Oligonucleotide primers were synthesised by Sigma-
Genosys (The Woodlands, TX, USA) as follows: (a) PSA (710bp),
22 cycles; forward, 50-GATGACTCCAGCCACGACCT-30; reverse,
50-CACAGACACCCCATCCTATC-30; annealing temperature, 571C;
(b) AR (590bp), 32 cycles; forward, 50-ATGGAAGTGCAGTTAGG
G-30; reverse, 50-CAGGATGTCTTTAAGGTCAGC-30; annealing
temperature, 571C; (c) neuron-specific enolase (NSE) (662bp)
(GenBank X51956), 40 cycles; forward, 50-GTTCTGAACGTCTGG
CTAAATAC-30; reverse, 50-CATTGAGTTATGGGGAAATGA-30;
annealing temperature, 601C; and (d) housekeeping gene (glycer-
aldehyde-3-phosphate dehydrogenase, 230bp), 25 cycles; forward,
50-TCAAGAAGGTGGTGAAGCAG-30; reverse, 50-CTTACTCCTTG
GAGGCCATG-30; annealing temperature, 571C (Jiang et al, 2006).
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sIn vivo prostate cancer (PC3) xenograft model,
chemotherapy, and radiation therapy
The PC3 tumour model was established as described previously
(Wang et al, 1999). Briefly, 4- to 6-week-old male athymic nude
mice (nu/nu) were obtained from the Frederick Cancer Research
and Development Center (Frederick, MD, USA). Cultured PC3 cells
were washed with and resuspended in serum-free medium.
Portions of the suspension (5 10
6 cells in 0.2ml) were injected
into the left inguinal area of the mice, which were monitored by
measuring tumour growth and body weight, and by general clinical
observation. Tumour-bearing mice were randomly divided into
multiple treatment and control groups (n¼5 per group). 25-
OCH3-PPD was dissolved in PEG400/ethanol/saline (57.1%:
14.3%:28.6%, v/v/v), and administered by intraperitoneal injec-
tion at doses of 5, 10, and 20mgkg
 1, 3 days per week for 4 weeks,
or 5 and 10mgkg
 1, 5 days per week for 4 weeks. The control
groups received the vehicle only. Gemcitabine (160mgkg
 1) and
taxotere (15mgkg
 1) were administered by intraperitoneal injec-
tion, once a week for 2 weeks. Mice receiving radiation were first
anaesthetised with a 70–100ml mixture of ketamine (20mgml
 1)
and xylazine (20mgml
 1) at a 6.7:1 ratio and then placed under a
specially designed lead shield so that only the tumours were
exposed to the radiation beam. g-Irradiation was administered
by a
60Co Picker unit (JL Shepard Co., Glendale, CA, USA) at a rate
of 0.66Gymin
 1. Animals received 3Gy of radiation once a week
for 3 weeks. When used in combination with gemcitabine or
taxotere, 25-OCH3-PPD was administered at a dose of 10mgkg
 1
(5 days per week). Animals were monitored for activity, physical
condition, body weight, and tumour growth. Tumour size was
determined by caliper measurements of two perpendicular
diameters of the implant every other day. Tumour weight (in
grams) was estimated by use of the formula 1/2a b
2, where a is
the long diameter and b is the short diameter (in cm). All animal
protocols were approved by the Institutional Animal Care and Use
Committee of UAB.
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Figure 1 Chemical structures and anticancer activities in vitro.( A) Structures of 25-OCH3-PPD, PPD, Rg3, and Rh2. (B) Antiproliferative effects of the
compounds on prostate cancer cells. LNCaP (B1) and PC3 (B2) cells were exposed to various concentrations of the four compounds for 24h followed by
assessment of cell proliferation by BrdUrd. All assays were performed in triplicate. (C) Induction of apoptosis in LNCaP (C1) and PC3 (C2) cells. These cells
were exposed to various concentrations of ginsenosides for 48h followed by assessment of apoptosis. All assays were performed in triplicate.
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sRESULTS
Ginsenosides decrease cancer cell growth in vitro
25-OCH3-PPD (from P. notoginseng) and the related P. ginseng
compounds, PPD, Rh2, and Rg3 (Figure 1A), were evaluated for
their effects on prostate cancer cell growth in vitro by use of the
MTT assay. Following incubation with various concentrations of
the compounds, amounts reducing growth by 20, 50, and 80%
(IC20,I C 50, and IC80) were calculated (Table 1). For both LNCaP
(p53 wild-type, androgen-dependent) and PC3 (p53 null, andro-
gen-independent) cells, 25-OCH3-PPD had the lowest IC50 values
(in the low mM range) compared with other ginsenosides tested
(Po0.01). 20(S)-protopanaxadiol and Rh2 also demonstrated
inhibitory effects, with values in the mid-mM range. Ginsenoside
Rg3 did not significantly decrease cell viability even in the high-mM
range. It is worth noting that Rh2 and PPD decreased the viability
of two noncancer fibroblast cell lines to a comparable extent as
observed for the prostate cancer cells, while 25-OCH3-PPD had a
lesser effect on these cells (Table 1).
Ginsenosides decrease cell proliferation
For both LNCaP and PC3 cells, an antiproliferative effect for 25-OCH3-
PPD was evident (Figure 1B, Po0.001). PC3 cells were generally more
sensitive to the ginsenosides than LNCaP cells. At 25mM,2 5 - O C H 3-
PPD inhibited LNCaP proliferation by 40% and PC3 cell proliferation
by 85% (Po0.01). Although 25-OCH3-PPD was consistently most
effective, Rh2 and PPD also decreased the proliferation of both cell
lines (Po0.05); the effects of Rg3 were minimal.
Ginsenosides induce apoptosis
In a dose-dependent manner, 25-OCH3-PPD induced apoptosis in
both LNCaP and PC3 cells (Figure 1C). 25-OCH3-PPD was the most
effective ginsenoside, demonstrating a more than six-fold increase
in LNCaP cells and a 10-fold increase in apoptosis in PC3 cells at
50mM (Po0.01). A concentration of 10mM caused a three-fold
increase in apoptosis in LNCaP cells. Ginsenoside Rh2 and PPD
showed activity only at higher concentrations. In both cell lines,
the effect of Rg3 was minimal.
Ginsenosides cause cell cycle arrest
In both LNCaP and PC3 cells, 25-OCH3-PPD induced cell cycle
arrest in the G1 phase in a dose-dependent manner (Figure 2,
Po0.01). Relative to the other compounds, 25-OCH3-PPD (at the
highest concentration, 25mM) had the most potent effects in
both cell lines. 20(S)-protopanaxadiol and Rh2 (at the highest
concentration, 50mM) altered the cell cycle, although these changes
were not as great as those induced by 25-OCH3-PPD. As in the
evaluation of cell viability, apoptosis, and proliferation, the effects
of Rg3 on the cell cycle were minimal.
Ginsenosides induce changes in expression of proteins
involved in regulating apoptosis and cell cycle progression
Possible mechanism(s) responsible for the antiproliferative, pro-
apoptotic, and cell cycle regulatory effects of the four compounds
were investigated by evaluating their effects on the expression of
various proteins involved in these processes (Figure 3). Demon-
strating how the compound affects proliferation, exposure of cells
to 25-OCH3-PPD caused the changes in expression of several cell
cycle regulatory proteins. In both LNCaP and PC3 cells, the
expression levels of MDM2, E2F1, Cyclin D1, and cdks 2, 4, and 6
were decreased, whereas the expression of p21
WAF/CIP and p27
KIP1
was increased (Figures 3A and B). 20(S)-protopanaxadiol and Rh2,
which had modest effects on the growth of cultured prostate cancer
cells, also altered the level of several of these proteins. Similar to
cells exposed to 25-OCH3-PPD, the levels of p21 and cleaved PARP
were increased by PPD and Rh2, and E2F1 and ckd4 were
decreased. In contrast, Rg3 did not alter the expression of these
proteins, with the exception of a slight increase in p21 in the
LNCaP cells. The p53 protein level in LNCaP cells was not altered
by any of the compounds (Figure 3A). These proteins are integral
in regulating cell cycle progression and cell proliferation, and
MDM2, E2F1, and cyclin D1 have been implicated in carcino-
genesis (Deb, 2002; Fu et al, 2004; Johnson and Degregori, 2006).
Downregulation of any or all of these proteins by 25-OCH3-PPD
may lead to antiproliferative and anticancer effects.
In addition to its antiproliferative effects, we also noted that
25-OCH3-PPD caused an increase in apoptosis in both PC3 and
LNCaP cells. We assessed the expression of several apoptosis-
related proteins, including Bax, Bcl-2, cleaved PARP, and several
caspases. Consistent with its effect on apoptosis, 25-OCH3-PPD
increased the expression of cleaved PARP and cleaved caspases
(Figures 3C and D). Both caspase-8 and -9 were activated,
indicating that the compound induces apoptosis via both the
intrinsic and extrinsic pathways. None of the three cleaved
caspases were increased in PC3 cells (Figure 3D), perhaps
accounting for the fact that LNCaP cells were more sensitive to
the apoptosis induced by ginsenoside. This result also suggests
Table 1 Growth inhibitory activity of the four ginseng compounds
Cell line Inhibitory concentration
a 25-OCH3-PPD (lM) PPD (lM) Rg3 (lM) Rh2 (lM)
LNCaP IC20 5.4 28.6 154.8 30.3
IC50 12.0 44.8 302.1 46.7
IC80 26.6 70.1 4500 72.0
PC3 IC20 1.5 12.9 176.7 15.7
IC50 5.6 29.3 266.5 35.7
IC80 20.6 66.6 402.0 81.4
IMR90-EEA IC20 10.4 22.8 297.8 58.2
IC50 110.1 82.6 387.1 74.4
IC80 4500 298.8 4500 95.0
IMR90-E1A IC20 6.2 1.3 52.7 28.0
IC50 275.7 18.2 146.8 48.5
IC80 4500 257.0 409.3 84.1
Abbreviations: PPD¼20(S)-protopanaxadiol; Rh2¼ginsenoside Rh2; Rg3¼ginsenoside Rg3; 25-OCH3-PPD¼20(S)-25-methoxyl-dammarane-3b,1 2 b, 20-triol.
aIC20,I C 50,
and IC80 are the concentrations that inhibit growth by 20, 50, and 80%, respectively, relative to the control.
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sthat the effect on apoptosis may rely on p53, because LNCaP cells
express wild-type p53, whereas PC3 cells are p53-null. 20(S)-
protopanaxadiol and Rh2 affected the expression of some of the
cell cycle-regulating proteins (Figures 3A and B), but to a lesser
extent than 25-OCH3-PPD. In both cell lines, these compounds had
minimal effects on apoptosis-related proteins. Ginsenoside Rg3
exposure led to a slight increase in p27, but this compound did not
have an appreciable effect on any of the other proteins.
25-OCH3-PPD decreases the expression of AR and PSA
The effects of 25-OCH3-PPD, PPD, Rg3, and Rh2 on the secretion
of PSA by LNCaP cells after 72h in culture were examined. For
comparison, resveratrol, a natural product known to have anti-AR
activity, was included (Mitchell et al, 1999; Jones et al, 2005). 25-
OCH3-PPD was as effective as resveratrol, decreasing the secretion
of PSA in a concentration-dependent manner (Figure 4A). 20(S)-
protopanaxadiol had a modest inhibitory effect only at 50mM; Rg3
and Rh2 did not exert any noticeable effect.
In addition, the effects of these compounds (50mM) on cellular
AR and PSA protein abundance after 24h of exposure were
examined (Figure 4B). 25-OCH3-PPD (lane 2) substantially
decreased AR and PSA levels, and PPD showed minor decreases
in expression (lane 6). Neither did Rg3 (lane 4) nor Rh2 (lane 5)
show any appreciable effect. The effect of 25-OCH3-PPD on AR
protein abundance was greater than that for resveratrol. As
determined by reverse transcriptase–polymerase chain reaction
after 24h of exposure of cells, 25-OCH3-PPD decreased both PSA
mRNA and AR mRNA (Figure 4C), demonstrating that it regulates
AR and PSA at the transcriptional level. In contrast, resveratrol
decreased the mRNA for PSA but had only a minor effect on AR
mRNA. In these cells, both 25-OCH3-PPD and resveratrol induced
the expression of NSE, a marker of neuroendocrine differentiation
that responds to AR inhibition (Murillo et al, 2001). These
observations are consistent with the idea that 25-OCH3-PPD affects
AR signalling at the AR protein level and that it has a
transactivational impact on PSA mRNA transcription, leading to
decreased cellular PSA synthesis and secretion into the medium.
25-OCH3-PPD inhibits the growth of human prostate
xenograft tumours in vivo
25-OCH3-PPD was evaluated in a mouse xenograft model of
androgen-independent prostate cancer. The compound was first
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Figure 2 Effects of ginsenosides on cell cycle progression of prostate cancer cells. LNCaP (A) and PC3 (B) cells were exposed to various concentrations
of the compounds for 24h followed by determination of cell cycle distribution. All assays were performed in triplicate.
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sgiven at 5, 10, or 20mgkg
 1day
 1 3 days per week for 4 weeks
(Figure 5A1). The highest dose significantly inhibited PC3 xenograft
tumour growth by 67% on day 27 (Po0.001). Even the lowest dose
of 5mgkg
 1 caused significant (30%, Po0.05) tumour growth
inhibition. In a subsequent experiment, mice received 5 or
10mgkg
 1 of 25-OCH3-PPD 5 days per week for 4 weeks. In this
case, tumour growth inhibition was more substantial. Tumours in
animals given the 5mgkg
 1 dose were only about half the size of
those in control animals (Po0.01). At the dose of 10mgkg
 1,2 5 -
OCH3-PPD inhibited tumour growth by 70% (Figure 5B1, Po0.005).
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Figure 3 Effects of ginsenosides on expression of various cell cycle-related (A and B) and apoptosis-related (C and D) proteins in human prostate cancer
cells. LNCaP (A and C) and PC3 (B and D) cells were exposed to various concentrations of the compounds for 24h, and the target proteins were
detected by immunoblotting with specific antibodies.
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s25-OCH3-PPD can be safely combined with conventional
anticancer therapies
25-OCH3-PPD was evaluated for its effect on androgen-indepen-
dent prostate cancer in combination with chemotherapeutic
agents (taxotere and gemcitabine) or radiation therapy. Taxotere
(15mgkg
 1) alone decreased tumour growth by 69%. When it was
used in combination with ginsenoside, there was a significant
increase in tumour growth inhibition to 94% (Po0.05, Figure
5C1). Similarly, although gemcitabine alone caused 80% growth
inhibition, the combination of gemcitabine and 25-OCH3-PPD
led to 496% tumour growth inhibition (Figure 5D1, Po0.01).
Radiation alone decreased the growth of the xenograft tumours by
39%; adding ginsenoside led to more substantial inhibition (70%,
Po0.05) (Figure 5E1).
Although mice receiving the chemotherapeutic agents or
radiation experienced temporary weight loss following treatment,
some of the weight was recovered afterwards. 25-OCH3-PPD did
not cause any substantial weight loss or any observable toxic effect
when administered alone and did not increase the toxicity of any
of the combined therapies (Figures 5A2, B2, C2, D2 and E2).
DISCUSSION
While cytotoxic agents are frequently used for traditional
chemotherapy, there is an ongoing search for more specific agents
that spare normal host tissues. Several natural products have
antiangiogenic and anticancer properties (Shibata, 2001; Li et al,
2006; Zhang et al, 2006). Such compounds generally have low
toxicity and can be protective against a variety of insults, such as
toxic chemicals and inflammation (Kim et al, 1998; Smolinski and
Pestka, 2003, Radad et al, 2004). On the basis of the assays in vitro,
we and others have demonstrated that a structure–activity
relationship exists among the ginsenosides, with the panaxadiols
generally being more active than the panaxatriols, and the
glycosylated compounds being less active as the number of sugar
moieties increases (Shibata, 2001; Popovich and Kitts, 2002; Wang
et al, 2007; Zhao et al, 2007). To our knowledge, 25-OCH3-PPD is
one of the most active ginsenosides that have been evaluated (Zhao
et al, 2007). More importantly, 25-OCH3-PPD was more cytotoxic
to the prostate cancer cells than to the fibroblasts. The apparent
cancer-specific effects of this compound could distinguish it
from other natural products. For example, although Rh2 and PPD
decreased the proliferation and viability of prostate cancer cells,
they were also cytotoxic to normal (although immortalised)
fibroblasts.
In confirmation of previous studies (Shibata, 2001; Kim et al,
2004; Cheng et al, 2005; Xie et al, 2005), Rh2 and PPD
demonstrated cytotoxic, antiproliferative, pro-apoptotic, and
regulatory effects on cell cycle progression. Although Rg3 is
marketed as an anticancer agent, it did not exert any appreciable
effect on the prostate cancer cells. It is likely that Rg3 functions as
an antiangiogenic compound (Shibata, 2001; Sengupta et al, 2004;
Yue et al, 2006) rather than as a cytotoxic agent. The related new
compound, 25-OCH3-PPD, demonstrated more potent effects, and
was more effective at lower doses than the other compounds.
Although both prostate cancer cell lines were responsive to 25-
OCH3-PPD (exhibiting decreases in survival and proliferation,
increases in apoptosis and cell cycle arrest in G1), there were
differences in their responses. These may be attributed to their
differential expression of p53 or differences in sensitivity to
androgen signalling.
In support of this, the differential anti-AR activities of the
ginsenoside compounds evaluated in the LNCaP model appear to
correlate with their growth inhibitory and pro-apoptotic efficacy.
The inhibition of AR expression and signalling suggest a
mechanism by which 25-OCH3-PPD could reduce the risk for
development of prostate cancer and function in the treatment of
both androgen-dependent and androgen-independent prostate
cancer. Most cancers in the latter category still express wild-type
AR, and ligand-independent AR signalling is essential for the
survival of even androgen-refractory prostate cancer cells (Yuan
et al, 2006). Therefore, by downregulating AR through a
nontranscriptional mechanism, 25-OCH3-PPD could eliminate
prostate cancer cells and/or make them more sensitive to
chemotherapeutic drugs or radiation. Although the role of PSA
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Figure 4 Effects on AR and PSA. (A) Comparison of the effects of 72-h exposure of LNCaP cells to increasing concentrations of 25-OCH3-PPD, Rg3,
Rh2, or PPD with resveratrol on secreted PSA levels in conditioned medium. (B) Effects of exposure for 24h to 50mM of 25-OCH3-PPD (lane 2),
resveratrol (lane 3), Rg3 (lane 4), Rh2 (lane 5), and PPD (lane 6) on cellular PSA and AR protein expression, as determined by western blots. (C)
Comparison of the effects of 25-OCH3-PPD with resveratrol on the steady-state level of mRNA transcripts of PSA, AR, and NSE after 24h of exposure, as
determined by reverse transcriptase–polymerase chain reaction. Neuron-specific enolase mRNA served as a molecular marker for neuroendocrine
differentiation.
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Figure 5 Antitumour activity and effects on body weight of 25-OCH3-PPD administered alone or in combination with taxotere, gemcitabine, or radiation
to nude mice bearing PC3 xenograft tumours. 25-OCH3-PPD was given by intraperitoneal injection at doses of 5, 10, or 20mgkg
 1day
 1, 3 days per week
for 4 weeks (A1 and A2), or 5 or 10mgkg
 1day
 1, 5 days per week for 4 weeks (B1 and B2). Taxotere (15mgkg
 1)( C1 and C2) or gemcitabine
(160mgkg
 1)( D1 and D2) was given on days 5 and 12 by intraperitoneal injection, radiation (3Gy) (E1 and E2) was administered on days 5, 12, and 19.
The dose of 25-OCH3-PPD was 10mgkg
 1, 5 days per week for studies combining ginsenoside with conventional therapy.
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sin the pathobiology of prostate cancer is not fully understood
(Williams et al, 2007), posttherapy reductions in PSA levels are
associated with improved survival in patients with metastatic
diseases (Fleming et al, 2006). Chemicals that reduce its
expression, as observed for 25-OCH3-PPD, could be useful in
treating the disease.
In addition to the effects on AR signalling, 25-OCH3-PPD
arrested cells in the G1 phase. 25-OCH3-PPD and two of the other
test compounds (PPD and Rh2) increased expression of p21 and
cleaved PARP proteins and decreased expression of MDM2,
E2F1, and cdks 2, 4, and 6. Although these results indicate that
ginsenosides inhibit cell cycle progression, there were differences
in the magnitude of the effects of the compounds. Individual
ginsenosides may have different interactions with proteins
involved in the regulation of the cell cycle. The presence of
additional ginsenosides or other natural compounds may lead to
undesirable or unexpected effects. These differences emphasise the
necessity of strict quality control to ensure the identity, purity, and
stability of the compounds.
Given the effects on proliferation and apoptosis-related proteins,
it is possible that downregulation of the MDM2 oncoprotein is, at
least in part, responsible for the observed cytotoxic effects of 25-
OCH3-PPD. We have previously noted that inhibition of MDM2
results in increased p21, decreased E2F1, decreased cell survival
and proliferation, induction of G1 cell cycle arrest, and an increase
in apoptosis, as well as in vivo antitumour effects (Zhang et al,
2003, 2004, 2005). Although further investigations are needed to
identify the exact mechanism(s) of action, this study provides
preliminary data about how 25-OCH3-PPD exerts its effects. The
effects of 25-OCH3-PPD on various proteins and their interrelation
are summarised in Figure 6.
To accomplish a preliminary evaluation of the in vivo
therapeutic effects of 25-OCH3-PPD, we examined the effects of
the compound alone or in combination with conventional
therapies in a mouse xenograft model of androgen-independent
prostate cancer. A dose of 5mgkg
 1 given 3 days per week led to
more than 30% tumour growth inhibition. When the compound
was given more frequently (5 days per week), the antitumour effect
was greater, with almost 50% inhibition of tumour growth. This is
noteworthy considering that ginsenosides administered intrave-
nously typically have half-lives of less than 20min (Qian et al,
2005a,b), and their bioavailabilities are usually lower than 20%
(Xu et al, 2003). Our study indicates that 25-OCH3-PPD is
sufficiently stable to exert an anticancer effect in vivo, even when
given only every 48h. Nevertheless, future pharmacokinetic
studies of this compound, in comparison with its analogues, will
increase the understanding of its mode of action and contribute to
the better design of preclinical and clinical trials.
When combined with either of the two chemotherapeutic agents,
taxotere or gemcitabine, 25-OCH3-PPD caused almost complete
tumour growth inhibition. These results are consistent with
previous studies showing that ginseng compounds can be safely
combined with other agents and may lead to improved antitumour
activity (Wang et al, 2006; Xie et al, 2006). Similarly, the
combination of radiation with 25-OCH3-PPD did not lead to any
increase in toxicity, and there was a slight increase in tumour
growth inhibition. It is possible that a longer treatment period may
demonstrate a greater additive or synergistic effect. Thus, addition
of the novel compound could improve the response of human
tumours to radiation or to chemotherapeutic drugs that are
currently used for the treatment of prostate cancer. It may also be
possible to combine 25-OCH3-PPD with lower doses of conven-
tional agents to achieve a strong antitumour effect, but with
decreased toxic side effects. It is noteworthy that we used relatively
high doses of chemotherapeutic agents in the combination study
and lower doses can be used in future studies to determine if
synergistic effects can be achieved between 25-OCH3-PPD and
these agents or radiation.
Although the four ginsenosides share a common core structure,
they have remarkably different effects on cancer cells. Of those
tested, 25-OCH3-PPD demonstrated the most potent cytotoxic,
antiproliferative, pro-apoptotic, and cell cycle regulatory effects.
Moreover, it produced strong antitumour effects against a model
of androgen-independent prostate cancer both alone and in
combination with conventional cancer therapies. These results
indicate that 25-OCH3-PPD may be an appropriate candidate for
further preclinical and clinical development as an antiprostate
cancer agent either alone or in combination with conventional
therapies. Further studies of its efficacy, toxicity, and pharmaco-
kinetics are necessary prior to human clinical trials. Although
the compound can be purified to 499% (Zhao et al, 2007), a
well-designed quality control procedure is needed. In addition, a
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Figure 6 Proposed mechanisms of action. The cartoon, showing the effects of 25-OCH3-PPD on various proteins, demonstrates how the compound
could exert its anticancer effects.
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ssynthetic method for generating 25-OCH3-PPD, if successful,
would ensure the consistency, potency, and purity of the
compound for human studies.
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